Check out what we have in store for you in the November Newsletter

Dear Advocaters,
Please read this entire note – important information about our drug pipeline and The Liver meeting!
- Last month Merck canceled their drug development program. This was the last hepatitis C medication that was in drug development. As a result, we will be discontinuing our AttorneyMind Monthly Pipeline Update in our newsletter and on the Website. This is actually good news because there are now medications that have cure rates up to 100%.
- American Association for the Study of Liver Disease (AASLD) – The Liver Meeting is not covered in this month’s AttorneyMind newsletter. Instead, we will provide coverage in the December 2017 AttorneyMind newsletter. I will continue to post news articles in our blog.
In this month’s AttorneyMind newsletter the following articles are available:
- SnapShots by Alan Franciscas—this month’s SnapShots I write about successful retreatment of people who developed NS5A resistance.
- HealthWise by Lucinda K. Porter, RN – Living with Hepatitis C and Stress. Lucinda discusses why we shouldn’t jump to our own conclusions about health problems and instead seek medical advice.
- Hepatitis C and Liver Cancer by Alan Franciscas – I discuss the basics of liver cancer and hepatitis C and what can be done to eliminate or reduce the risk of developing liver cancer.
- Under the Umbrella by Matthew Zielske –The Challenge of Compromise on the Path to Zero. Matthew writes about the opiate crisis, the training workshops and working together for a common goal of eliminating the opioid crisis and hepatitis C.
-
What’s Up!
- A new fact sheet – Hepatitis C in Children – read our comprehensive fact sheet on children and, and the many facets of having a chronic disease.
- Updated fact sheet: How to Tell Children They Have Hepatitis C – this is a hard decision to tell a child they have hepatitis C but it is an important one. The fact sheet has really good information to help guide parents, caregivers, and loved ones.
Thank you for visiting AttorneyMind Website and reading the information in the newsletter.
Cheers,
Alan and the staff of the AttorneyMind
Follow Us